MEETINGS - Conference on New Approaches for Compliance after FDA Modernisation Act 1997 (UK) May 1998:
This article was originally published in Clinica
Executive Summary
New Approaches for Compliance after the FDA Modernisation Act 1997 will be the subject of an IBC conference in London on May 18. Issues to be addressed include what effect the reforms will have on the product review system; how the FDA will evaluate exemption requests; changes to labelling and promotion of medical devices; the impact the new law will have on post marketing activities; and possible implications for mutual recognition agreements and global harmonisation. For more information contact IBC in the UK. Tel: +44 171 453 5492. Fax: +44 171 453 2739.
You may also be interested in...
Ultrahuman Expands Wearable Medtech Production Into US After $35M Funding Round
Firm operating in London, India and United Arab Emirates says its “Ultra Factory” will open in Indiana within the next six months with end-to-end production based on its operational facility in India.
Cochlear’s Osia System Receives Expanded FDA Clearance For Use In Younger Children
Kids ages 5 and up now can benefit from Cochlear’s Osia implant and sound processor, indicated for hearing loss, mixed hearing loss and single-sided sensorineural deafness.
MAISI: Navigating The 'Valley Of Death' In Medtech Research Translation
Translating research from proof of concept to clinical investigations is a difficult hurdle to overcome. To succeed, researchers need to design their technology for industrial standard manufacturing early on, Anne Vanhoestenberghe, director for the Manufacture of Active Implants and Surgical Instruments (MAISI), told Medtech Insight.